Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4809974 | 0.89 | DPP4 (0.71) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL4809964 | 0.89 | DPP4 (0.71) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL14045563 | 0.88 | DPP4 (0.54) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL4817566 | 0.85 | DPP4 (0.66) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL14148451 | 0.81 | DPP4 (0.62) | DPP4 | |
| SCHEMBL8283962 | 0.81 | DPP4 (0.63) | DPP4CHRM1CHRM3KCNH2 | |
| SCHEMBL8284557 | 0.80 | DPP4 (0.60) | DPP4 | |
| SCHEMBL14045473 | 0.80 | DPP4 (0.82) | DPP4 | |
| SCHEMBL14045567 | 0.80 | DPP4 (0.57) | DPP4KCNH2 | |
| SCHEMBL14148712 | 0.79 | DPP4 (0.54) | DPP4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432262-B2 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-07 | — | — | US | disclosed |
| US-7393847-B2 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2008-07-01 | — | — | US | disclosed |
| US-20070142383-A1 | Imidazopyridazinediones, Their Preparation And Their Use As Pharmaceutical Compositions | ECKHARDT MATTHIAS | 2007-06-21 | — | — | US | disclosed |
| WO-2005087774-A1 | IMIDAZOPYRIDAZINE DIONES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142383-A1 | Imidazopyridazinediones, Their Preparation And Their Use As Pharmaceutical Compositions | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 624/4885CHRM2 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.